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1. Introduction
Lymphoma is the most common neoplasm of the canine hemolymphatic system. It represents
about 15% of all malignant neoplasms. It has a very poor prognosis, the mean survival with
high grade non Hodgkin’s lymphomas being two months without treatment [1]. Incidence is
increasing.
Lymphomas in dogs, as in humans, can be divided into numerous types depending on the cell
line involved and their immunophenotype [2]. T lymphomas have a worse prognosis than B
lymphomas and late clinical stages obviously have a very short survival period.
Lymphomas are known in human medicine to respond to chemotherapy, and some of them
can even be cured by complex chemotherapy protocols, although severe side effects are noted.
Chemotherapy protocols have also been developed for dogs in the last 40 years. They have
proved to be effective for the overall survival of the treated animal. Although the order of drug
administration and duration of the maintenance part of the protocol vary considerably, most
oncologists agree that a doxorubicin-based (eg CHOP) combination chemotherapy protocol
provides the longest period of disease control and overall survival [3].
Even with chemotherapy, survival is relatively short and adjuvant therapies have been
developed to improve prognosis. Immunotherapy protocols are of particular interest for this
purpose as they may arm immune system cells against the abnormal proteins synthesized by
cancer cells [4]. It is a selective way of destroying cancer cells and a treatment with much fewer
side effects than chemo- or radiotherapy.
The immune system can destroy cancer cells by different methods:
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• Synthesis of TNF-α (tumor necrosis factor alpha) and an oxygen intermediate such as nitric
oxide by macrophages activated by IFN-γ (interferon gamma)
• Activation of NK (natural killer) cells by IL-2 (interleukin 2)
• Adsorption of an antibody against tumor cell antigens targeting macrophages and cytotoxic
T lymphocytes.
• Activation of CD8+ T lymphocytes by an MHC(major histocompatibility complex) -
mediated cell contact mechanism between antigen-presenting cells (APCs) and CD8 cells
Several kinds of immunotherapy protocol are available both in human and veterinary
medicine [4, 5, 6, 7]. Heat shock proteins (HSPs) such as gp96 or HSPs70 which are synthesized
by the cells submitted to stress are advantageous vaccination adjuvants due to their chaperone
properties and their role in antigen presentation [8]. As chaperone molecules, almost all the
cell peptides are associated with these proteins and HSP purification provides a fingerprint of
the cell’s protein synthesis [9]. This is particularly useful for cancer cells which synthesize
numerous abnormal proteins during their natural progress [10]. These cells being genetically
unstable, their abnormal protein synthesis differs from patient to patient and during the course
of the disease. The HSPs and their associated peptides (AAPs) have special receptors (CD91)
on dendritic cells which allow the internalization of the AAPs and their modification in order
to be expressed at the surface of class I HLA proteins on the cell membrane, triggering
activation of the CD8 T cells if they are abnormal [11].
Cancer cells are stressed by the mechanical and metabolic characteristics of the tumour. They
synthesize many HSPs [12]. We thus isolated these proteins in order to make an autologous
vaccine against the tumour. The HSPs were purified using a hydroxylapatite powder (HA)
column. The powder carrying the HSPs was then injected subcutaneously to stimulate the
immune system’s response to the tumour.
Purification of HSPs using classical way is long and tedious. The use of hydroxylapatite
powder allows a much faster purification process. Hydroxylapatite chromatography has been
described by Tiselius in the early seventies. Hydroxylapatite chromatography is an adsorption
chromatography. The adsorption mechanism is very poorly understood. The surface of the
material is occupied bu Ca++ and PO4-. These ions are supposed to interact with the chemical
groups of the proteins. However, post synthesis treatment such as sintering or spray- drying
process modify the physico-chemical properties of the material surface. Furthermore, the
interaction of the material surface with biological fluids triggers epitaxial growth of carbonated
apatite at the surface of the material [13].
It was decided that the proteins purified will be injected carried by the particles for several
reasons: the hydroxylapatite particles have been described as vaccine adjuvant, they are
phagocytosed by the APCs and can deliver the proteins directly in the APCs, they trigger an
afflux of APCs at the injection site [14]. Most of the adjuvants used in antiinfectious vaccines
are nano or microparticular.
The aims of this study was to check the feasibility of this protocol using HA-particles with
dogs suffering of high grade lymphoma and to know if secondary effects were detected.
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2. Materials and methods
2.1. Dogs to be treated
Two dogs (Poodle, 6 years, Jagdterrier, 8 years ) suffered from polyadenopathy without any
sign of immune deficiency. One dog (mixed breed, 10 years) had a liver metastasis. The last
one had a cutaneous form. Their general condition remained reasonable, with no real weight
loss or fever. One dog (Poodle) had a splenomegaly. The blood numeration revealed that the
white cells and calcaemia for both dogs were in the normal range. Node biopsies were
performed. One was sent to the pathologist and the other was frozen (-20°C) and used to
manufacture the vaccine. Disease staging was performed using the WHO-staging criteria for
canine lymphoma.
A chemotherapy treatment was proposed by the physician but rejected by the dog's owners
due to side effects and an informed consent was signed.
After vaccination, the dogs were subjected to a clinical examination whenever they came for
the following injection and side effects noted. The volume of a control node was externally
measured.
2.2. Toxicity and response assessment
The side effects were graded every week for the first month and every month for the next five
months according to the National Cancer Institute’s common Toxicity Criteria (version 2.0).
The dogs were also submitted to a physical examination at the same frequency to assess their
clinical response. A complete response (CR) was defined as the disappearance of all the nodes
and metastasis for at least 4 weeks. A partial response (PR) was defined as a decrease by at
least 50% of the product of the 2 longest lengths of all the nodes without the appearance of
new lesions for at least 4 weeks. A minor response (MR) was defined as a decrease by less than
50% using the same criteria. Stable disease (SD) was defined as the same criteria unchanged
for at least 4 weeks. Progressive disease (PD) was defined as an increase by >25% of the product
of the 2 longest lengths of all the nodes for at least 4 weeks or when new lesions appeared.
2.3. Hydroxylapatite powder characteristics
Hydroxylapatite powders (Fig. 1) can be used for adsorption chromatography under atmos‐
pheric or high pressure. In order that the protein solution did not fill in the column and to
avoid the compaction, the powder was spray-dried then sintered at 1000°C.
The HA was transformed into a ceramic powder according to the following protocol. The
synthesized calcium phosphate was suspended in a slurry which is liquid, spray-dried, then
sintered. The spray-dried material was heated almost to fusion temperature which favors the
migration of matter between the grains and the formation of bridges. As the surface energy
was smaller for large than for small grains, their size increased and the distance between the
grain centers and the particle surface area decreased.
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Powder characteristics
Nature of the charged groups PO4 3-, OH-, Ca2+
Electrocinetical potential (mV) -35
Hydrophobicity +
Surface pH 7,8
Granulometry (µm) 0-25
Surface area (m2/gr) 4
Shape spherical
Table 1. Characteristics of the powder
The sintering considerably reduced the surface area making the amount of proteins adsorbed
on the powder lower. It also stabilized the powder structure. The powder was submitted to
dissolution/ precipitation processes when soaked inside a saline solution [13]. The modifica‐
tion occurring at the powder surface affected the adsorption properties of the powder. The
reduced surface area decreased the interactions with the saline solution containing the
proteins. There was a microporosity between the ceramic grains inside the same particle
allowing the protein solution to diffuse inside the particles. The characteristics of the powder
used in this experiment was given in table 1
As the chromatography was carried out under atmosphere, the granulometry of the powder
was an important factor in order to avoid any plugging of the column. The HSPs could be
eluted from the powder by 200-300 mM NaCl solutions. The powder solution in NaCl was not
stable enough to be injected as it decanted too fast in the syringe. Thus to improve the
injectability the powder was put in suspension in a 2% solution of carboxymethylcellulose in
20 mM NaCl.
2.4. Vaccine manufacturing protocol
The tumor tissue and all the materials used to prepare the vaccine were handled in sterile
conditions under a laminar flow. The frozen tumor (200 mgr) tissue was homogenized using
a bead tissue homogenizer. 1 ml of NaHCO3 (30 mM, pH 7) was added for 1 ml of homogenate.
The resulting homogenate was then centrifuged at 1000 g for 15 mn at 4°C to remove all cell
fragments.
The supernatant containing the cytoplasmic proteins was used for protein purification by HA
column chromatography as follows: a) two precipitations with ammonium sulphate (first at
50% and then at 70%) recovering the pellets. The last pellet was resuspended in 1 ml phosphate
buffer (20 mM, pH 7). The column was filled (chromatography columns, Poly-prep, Cat.
731-1550, Bio Rad) with 0.2 gr of HA (0-25 µm), equilibrated with 10 volumes of phosphate
buffer (20 mM pH7). The resuspended pellet was then added. The column was then washed
with 3 ml of a 100 mM NaCl solution (fig.2).
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The powder was then suspended in 5 ml carboxymethylcellulose (CMC) solution (2% in 20mM
NaCl). 0.5 ml of this solution was used for each vaccine shot.
Figure 2. Autovaccine manufacturing scheme
Figure 1. SEM of the HA-powder used for the vaccine.
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0.2 ml of the previous solution was used to make electrophoretic control. The solution was
centrifuged at 1000g 30 for seconds. The supernatant was discarded and the powder in the
pellet washed with 0.1 ml of a 0.5 M NaCl solution. The solution was again centrifuged and
the supernatant was used for a SDS-Page and for protein quantification using UV spectrometer.
10 µl of the solution was also used for dot blot with anti HSP70 and anti gp90 antibodies on a
nitrocellulose membrane. The antibody labelling was evidenced using a westernbreeze™
(invitrogen) kit according to the manufacturer instructions.
2.5. Vaccination protocol
The dogs were injected with 0.5 ml (about 40 µg of proteins) of the vaccine subcutaneously on
day 0. The dose schema consisted of 0.5 ml/dose every week for one month, followed by one
dose every month for four months.
2.6. activation of TLR2 and 4
Some HSPs are TLR (Toll like receptor) agonist and the TLR activation was checked using two
cell lines secreting an embryonic phosphatase alkaline when the TLR 2 or 4 are stimulated.
Two cell lines were used for TLR receptor stimulation. HEK-BlueTM-hTLR2 and HEK-BlueTM-
hTLR4 cells (invivogen –France) were grown in DMEM supplemented with 10% fetal calf
serum and 0,5% normocin (invivogen-France) to avoid mycoplasma contamination. 20000 cells
were introduced in wells of 96-well plate, 4 hours later 20 µl of different concentrations of the
vaccine was added and incubated at 37°C for 20 hours. Then the medium was removed and
replaced by 180 µl of resuspended QUANTI- blueTM (Invivogen) and incubated for 1 hour
and the positivity evaluated. The negative control was the HA- powder without any protein
immobilized on its surface. The minimal concentration turning blue the medium was noted.
It was estimated that the vaccine was functional when the minimal active concentration was
less than the vaccine concentration.
3. Results
All the vaccine dilutions stimulated the TLR 4 but not the TLR2. The negative control (HA
powder) did not stimulate any TLR. The SDS PAGE revealed two bands in the 95 kDa region
which were previously demonstrated to be HSPs rich bands (fig. 3) The dot blots revealed that
all the vaccine contained gp96 and HSP70 but the amount was different (fig.3 and 4).
Neither dog showed side effects after the injections, whether systemic or local. Two showed a
decrease in nodule volume of less than 50% following the first month of injections and were
rated MR. The other were rated SD. All dogs were rated PD about one month before they died.
No sign of infection such as fever was observed during the first month of vaccination. The
Jagdterrier was diagnosed with an abscess of the collar by the fourth month, which was cured
surgically. The lung radiographs did not reveal any lung metastases. The blood count did not
show any anomaly in the white cell count up to the last month of survival.
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Figure 3. L1 was obtained after washing the powder with 0.3M NaCl, L2 was obtained after washing at 0.02M, L3 was
obtained with 0.5M. At 0.02M almost all the contaminant proteins are eluted from the powder. At 0.3 M, the remain‐
ing proteins after the 0.02M elution are located in the 95 and 70 kDa zone. The 0.5 M column shows that after after
0.3 M there is almost no proteins remaining on the powder.
The poodle was euthanazised 11 months, and the Jagdterrier 6 months, after the disease was
discovered. During their survival period, both dogs had a normal activity. The Jagdterrier was
still hunting two weeks before to be euthanazied. The two other dogs were euthanazied at 155
and 173 days (table 2). The mean overall survival time is 210 days.
Dog number Breed Histology Stage OS Immunophenotype
1 Jagd terrier Centoblasticpolymorphic IIIb 330 B cell
2 Poodle Centroblasticpolymorphic IIIb 180 B cell
3 mixed Centroblasticpolymorphic IVb 173 B cell
4 cocker cutaneous IVb 155 T cell
Table 2. Characteristics of the dogs treated by the vaccination protocol and overall survival time (OS) in days.
Hydroxylapatite (HA) Powder for Autovaccination Against Canine Non Hodgkin’s Lymphoma
http://dx.doi.org/10.5772/55129
507
Figure 4. Dot blot after anti gp90 labelling
Figure 5. Dot blot after anti HSP70 labelling
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4. Discussion
This experiment showed the feasibility of this protocol as an autologous vaccine for cancer in
dogs in veterinary practice. We have also developed an in vitro test to assess the functionality
of purified heat shock proteins. This test checks in a few minutes the vaccine’s ability to
stimulate antigen-presenting cells (APCs) through toll-like receptor (TLR) activation. Even if
the sample size is small, the dogs’ overall survival (210 days) was much higher than expected,
as the average OS for this type of pathology is two months. In larger series of stage Vb
lymphomas associating chemotherapy and the same vaccine protocol, we could demonstrate
that after vaccination the dogs showed a delayed cutaneous hypersensibility after their own
tumor antigen injection in the derm (Marconato, unpublished results).
High grade lymphomas in dogs are an interesting model for cancer vaccines because survival
is very short, so the effect on OS is very easy to measure. The clinical efficiency of vaccine is
not always related to the vaccine’s effect on biological parameters. Models with a short life
expectancy are thus of interest. Furthermore vaccination without the use of other drugs is of
particular interest.
The amount of proteins used in this vaccine was justified by the different experiments
published about autovaccines using HSPs in animals and humans. Furthermore we checked
that the amount of proteins could activate 20000 APCs in vitro. The presence of the tumor
proteins at the surface of the HA-particles allows the activation of the TLRs. It indicates that
the proteins are immobilized at the surface of the particles and their adsorption does not
denaturize these proteins.
Cancer vaccines are the focus of great interest. Although cancer cells synthesise abnormal
proteins, they are are not recognised by the immune system. Different immunosuppression
mechanisms by cancerous tumours have been described [15]. The use of multiantigen vaccines
could reduce the cancer cell’s “invisibility” to the immune system compared to monoproteic
vaccines. Different kinds of immune therapy are under investigation. Cell engineering
immunotherapy protocols have been tested, including activation of dendritic cells in vitro by
tumour antigens before being reinjected into the patient [16]. Other trials concern amplification
of the intratumoural lymphocytes (TILs) in vitro [17] before being reinjected into the donor.
Recently, different types of antibodies were approved for the oncology field, in particular
antibodies against VEGF (Vascular endothelial growth factor) to inhibit tumour vasculariza‐
tion [18, 19].
Heat Shock Proteins (HSPs) have proved to be of therapeutic interest in human medicine for
some applications. In order to be useful as a cancer vaccination, these HSPs must be made
available to APCs. HA-powder is a good material for use as a vector of HSPs to APCs. It has
been shown that when injected in the dermis or subcutaneous tissue, it triggers a foreign body
reaction and that the cells of this foreign body reaction could be transfected with a DNA
molecule carried by the particles [20]. It suggests that, further to DNA vectorisation, the
particles could help in the transfection of HSPs and their associated peptides in APCs.
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Although gp96 has been described as able to stimulate TLR4, it is not sure that these proteins
are the only proteins responsible for TLRs stimulation in this case. There are contaminating
proteins in various bands of the SDS which could interfere with the TLRs. The non stimulation
of the TLR2 indicates that the TLR4 is not activated by contaminating endotoxins.
Hydroxyapatite has been used as an adjuvant for various infectious vaccines such as diphtheria
and tetanus [21]. The Hydroxyapatite lattice is a hexagonal structure which allows numerous
substitutions. Ions and small amino acids can thus be trapped in the HA lattice. Consequently,
HA powder has been used to purify DNA, proteins or even viruses from biological solutions
[22]. In this case, the surface properties of the particles allowed both the purification of HSPs
and their use as a vector to APCs and as an adjuvant.
The HA-powder characteristics seems well suited for its role of cancer vaccine adjuvant. The
granulometry range allows the phagocytosis by the APCs as it was demonstrated previously
[14]. Furthermore, the grain boundaries in each particle is degraded by the cells making the
particles fragmented and thus decreasing the real granulometry a few days after injection. It
was also demonstrated that the phagocytosis of these particles by the APCs induced the
synthesis of various cytokines and lymphokines necessary for the cross-priming of the CD8.
The HA-adjuvant effect does not seem to be due to TLR activation as HA-particles alone do
not trigger TLR2 and 4 activation. Other mineral adjuvants such as aluminum oxide have been
demonstrated to activate the inflamasome. The inflamasome is a multi-protein complex
involved in the production of mature IL-1β. The alumn-induced release of IL-1β in macro‐
phages is done under activation of the NLRP3 [23]. It is suggested from unpublished results
that the adjuvancy effect of the HA-particles is also due to the inflamasome activation.
Tumor associated antigens show a very poor antigenicity. Thus the presence of an adjuvant
like calcium phosphate particles is essential in order to increase the visibility of these antigens
by the patient immune system.
This method was used in a short pilot study in humans and proved to be very safe, as only
local effects (erythema) were reported in some patients (24). Although it was not the goal of
the pilot study, some remission in the extent of the tumour was observed and constituted a
good proof of concept. Gp96 has already been used in human medicine to treat a series of
patients with indolent non Hodgkin’s lymphoma [23]. The results are difficult to compare, as
the patients could have been treated by chemo- or radiotherapy more than six weeks before
the vaccination protocol. However, at three months most of the patients were rated SD,
including those who were resistant to previous therapy. No patients suffered side effects.
5. Conclusions
The HA-particles are essential in this protocol both for their adsorption properties for proteins
of interest and their adjuvant properties. They constitute a tool which allows to purify tumor
associated antigens in a fast and reproducible way.
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The overall survival of the four dogs was much better than expected. These preliminary results
nonetheless show that the technique is feasible in private veterinary medicine. They are
consistant with other results obtained with canine osteosarcomas or with a series of stage Vb
lymphomas treated by chemotherapy and this protocol.
The association of the HA-particles to tumor associated antigens and HSPs did not trigger any
adverse effects, confirming the safe results obtained for other applications in human medicine.
This technique could also be combined with conventional chemo- or radiotherapy to increase
the animal’s overall survival.
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